Observational, bi-directional (prospective and retrospective) study for patients with newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021; irrespective of histology - OLIVIA

Study identifier:D133HR00051

ClinicalTrials.gov identifier:NCT07167433

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Ovarian Cancer epidemiology and care in Brazil: A Multicenter Perspective (OLIVIA Study) Observational, bi-directional (prospective and retrospective) study for patients with newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021; irrespective of histology

Medical condition

ovarian cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

Female

Estimated Enrollment

250

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 19 Sept 2025
Estimated Primary Completion Date: 31 Mar 2026
Estimated Study Completion Date: 31 Mar 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria